Lite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow LITS
Lite Strategy, Inc. (LITS) Piotroski F-score
Lite Strategy, Inc.'s Piotroski F-score for fiscal 2024 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 5 | 2.00 |
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | 0.00 |
| FY2021 | 4 | (2.00) |
| FY2020 | 6 | 2.00 |
| FY2019 | 4 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 21.92% | (21.32%) | Pass | 1 |
| Positive operating cash flow | (50.47m) | (52.48m) | Fail | 0 |
| Rising return on assets | 21.92% | (21.32%) | Pass | 1 |
| Cash flow above net income | (68.25m) | (20.65m) | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 4.88 | 5.29 | Fail | 0 |
| No new shares issued | 6,663,000 | 6,663,000 | Pass | 1 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.81 | 0.33 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| LITS Lite Strategy, Inc. | 5 |
| EDSA Edesa Biotech, Inc. compare | 3 |
| CRVO CervoMed Inc. compare | 2 |
| LBPS 4D pharma PLC Sponsored ADR compare | — |
| NNVC NanoViricides, Inc. compare | — |
| EXOZ eXoZymes Inc. compare | — |
| FLNA Cassava Sciences, Inc. compare | — |
| IRLA Quince Therapeutics, Inc. compare | — |
| LIANY LianBio Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover